Tensi+ has been awarded the ACP Industry Innovation Award 2026, recognising its contribution to advancing continence care.
We are excited and proud to share that Tensi+ has been awarded the Association for Continence Professionals (ACP) Industry Innovation Award.
The ACP awards celebrate innovation, excellence and improvements in patient outcomes. This recognition highlights Tensi+ as a forward-thinking solution that supports people living with Overactive Bladder (OAB).
Tensi+ is a non-invasive device designed to help manage symptoms such as urinary urgency, frequency and nocturia. By offering a drug-free treatment option that can be used at home, Tensi+ provides a convenient and empowering solution for patients looking to take control of their condition.
Tensi+ also offers clear benefits for the NHS, such as:
Cost savings versus pharmacological and invasive interventions
Aligns with Getting It Right First Time (GIRFT) and MedTech initiatives
Supports Value-Based Procurement by reducing pathway costs, not just product cost
Contributes to NHS Net Zero targets by reducing hospital appointments
Receiving the ACP Industry Innovation Award reflects the positive impact Tensi+ is already having within continence care.
It demonstrates our ongoing commitment to developing solutions that address real patient needs and support healthcare professionals in delivering effective care.
What makes this award so special is seeing first-hand the difference Tensi+ is making to patients living with an overactive bladder, we’ve had the privilege of hearing their stories, and knowing we’re helping improve their day-to-day lives is what truly matters.
Jacqui Preston, Senior Product Manager
